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Abstract Temporary inhibition of the cysteine proteinases pa- 
pain and cathepsin L was observed with several hairpin loop 
mutants of recombinant chicken cystatin at enzyme concentra- 
tions above nanomolar. Kinetic modelling of inhibition data, gel 
electrophoresis and amino acid sequencing revealed that reap- 
pearance of papain activity is due to selective cleavage of the 
Gly9-Ala ~° bond in the N-terminal binding area of the chicken 
cystatin variants, resulting in truncated inhibitors of lower affin- 
ity. Cleavage of the same bond by contaminating papaya pro- 
teinase IV was ruled out by previous purification of papain and 
suitable control experiments. According to the proposed kinetic 
model, cleavage occurs within the enzyme-inhibitor complex with 
first order rate constants ktemp of 2.3 x 10 -3 up to 5 x 10 -t s -t. A 
similar kt, m IKm ratio was found for all mutants (0.7 × 10 6- 
2.1 x 10 6 s-?'.M-1); it is almost identical with the k,~JKm ratio of 
the peptide substrate Z-Phe-Arg-NHMec. These results suggest 
that distorted contacts of one of the hairpin loops affect binding 
q~f the N-terminal contact area in a way that covalent interaction 
q:~f the Gly9-Ala 1° bond with the active-site Cys residue of papain 
tan occur and the bond is cleaved in a substrate-like manner. 
~ey words: Cysteine proteinase inhibitor; Papain; Cathepsin L; 
Chicken cystatin variant; Inhibition kinetics; Temporary 
nhibition 
I. Introduction 
Temporary inhibition, i.e. the reappearance of enzymatic 
tctivity after initial formation of an enzyme-inhibitor complex, 
1as been frequently observed with trypsin-like serine pro- 
einases and their protein-type inhibitors [1-3]. For the first 
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4bbreviations: Boc-, t-butyloxycarbonyl-; Bz-, benzoyl-; AV55, AEF- 
S1M, M29I, AV55, M89L] chicken cystatin; AV55-$56, AEF-[S1M, 
M29I, AV55, AS56, M89L] chicken cystatin; AP103-L105, AEF-[S1M, 
M29I, M89L, AP103, AWl04, ALl05] chicken cystatin; AI102-Q107, 
~EF-[S1M, M29I, M89L, All02, AP103, AWl04, ALl05, AN106, 
-IQ 107] chicken cystatin; E-64, L-3-carboxy-2,3-trans-epoxy-propionyl- 
leucylamido-(4-guanidino)butane;-NHMec, 7-(4-methyl)-coumaryl- 
amide; -NHPhNO2, p-nitroanilide; PPIV, papaya proteinase IV (glycyl 
endopeptidase, EC 3.4.22.25); rCC, AEF-[S1M, M29I, M89L] chicken 
cystatin, (recombinant chicken cystatin); Suc-, succinyl-; Z-, ben- 
zyloxycarbonyl-. 
time we have also observed temporary inhibition of the cysteine 
proteinases papain and cathepsin L during interaction with 
recombinant chicken cystatin variants bearing substitutions or
deletions in one of the two hairpin loop binding regions [4]. In 
this report we present kinetic and structural data describing the 
temporary inhibition of papain and propose a putative model 
for its molecular mechanism. 
Earlier observations of a loss of inhibitory capacity of natu- 
ral chicken cystatin and cystatin C during interaction with 
papain [5] were later explained as the effect of contaminating 
papaya proteinase IV (PPIV), which is not inhibited by cys- 
tatins but cleaves pecifically the conserved glycyl bond within 
their N-terminal portion [6]. In order to exclude artifacts due 
to PPIV contamination, the papain used in this work was care- 
fully repurified and control experiments with purified PPIV 
were performed. 
2. Materials and methods 
2.1. Materials 
AEF-[S1M, M29I, M89L] chicken cystatin (rCC) is a recombinant 
chicken cystatin molecule which behaves like the unphosphorylated 
form of the natural inhibitor [7]. Molecular cloning and expression of 
recombinant chicken cystatin variants have been described elsewere 
[4,7-9]. Human cathepsin B (EC 3.4.22.1) and human cathepsin L (EC 
3.4.22.15) were purchased from Medor (Herrsching) or Calbiochem 
(Bad Soden/Ts.) and used without further purification. 
2.2. Purification of papain 
Papain (Sigma Type III) was applied to a cation-exchange column 
(S-Sepharose, HiLoad 16/10, Pharmacia) in 0.05 M sodium acetate 
buffer, pH 5.0 [10]. The proteins were eluted with a linear gradient of 
0.0022 M sodium acetate/ml from 0.05 M to 0.5 M at a flow rate of 
5 ml/min. A similar procedure was used for the purification of papain 
from Boehringer (Mannheim). Papaya proteinase IV (PPIV) activity 
was assayed in 0.1 M phosphate buffer pH 6.8, 2 mM EDTA, 0.015% 
Brij 35, using the substrate Boc-Ala-Ala-Gly-NHPhNO2, and discrimi- 
nated from papain activity by its inhibition with E-64 and lack of 
inhibition with chicken cystatin [11,12]. Active papain concentration 
was determined by titration with E-64 [13]. 
2.3. SDS-PAGE 
SDS-PAGE was performed in a 10-20% polyacrylamide g l follow- 
ing the procedure of Laemmli [14]. The amount of protein was deter- 
mined by densitometry with an UltroScan XL (Pharmacia LKB). 
2.4. Amino acid sequencing 
Amino acid sequence analysis was done with a gas-phase sequencer 
473A (Applied Biosystems GmbH, Weiterstadt, Germany) following 
the instructions of the manufacturer. 
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2.5. Inhibition kinetics 
Cysteine proteinase activity was measured incontinuous kinetic as- 
says using the fluorogenic substrates Z-Phe-Arg-NHMec, Bz-Arg- 
NHMec and Suc-Leu-Tyr-NHMec (Bachem, Heidelberg) in a Kontron 
spectrofluorometer SFM-25 equipped with a 4-cell changer and con- 
trolled by an IBM-compatible personal computer [15]. Product concen- 
tration data were collected digitally for subsequent evaluation and 
kinetic modelling (see section 2.6). All assays were performed at 30°C 
in 1.2 ml of 0.3 M sodium acetate buffer pH 5.5 containing 1 mM 
dithiothreitol, 2 mM EDTA and 0.015% Brij 35. Appropriate substrates 
and substrate concentrations were selected allowing long-time continu- 
ous kinetic assays with neglegible substrate depletion (< 5%). Rate 
constants and Ki values were corrected for competition with the sub- 
strate. Active concentrations of the inhibitor variants were determined 
from inhibition experiments under equilibrium or incomplete itration 
conditions performed with defined concentrations of papain (titrated 
with E-64) or cathepsin L (titrated with standardized chicken cystatin) 
as described [4]. 
2.6. Kinetic modelling 
Testing of kinetic models for consistence with the progress curves 
obtained under different experimental conditions was performed with 
the simulation program FLUSIM [15]. Briefly, the proposed mecha- 
nism (see Fig. 1) is described by the following equations: 
d[EI~]/dt = kon~IE][I J - koff~fEI J - kt~mp[EI~] (1) 
d[EIb]/dt = ko.b[E][Ib] - ko~[EIb] + kt~mp[EI.] (2) 
[El = [Et] - [EIa] - [EIb] (3) 
v = vo[E]/[Ed (4) 
d[P] = v.dt (5) 
where [El is the concentration f free enzyme; [I~] and [Ib] are the 
concentrations of free unmodified and free converted (cleaved) inhibi- 
tor, respectively, [El,] and [Elb] the concentrations of the corresponding 
enzyme-inhibitor c mplexes and k .... konb, korra, kofeo the corresponding 
rate constants; [Et] is the total enzyme concentration; v the actual 
reaction rate, v0 the initial reaction rate (before addition of the inhibi- 
tor), and [P] the actual product concentration. The differential equa- 
tions (1), (2), and (5) were integrated numerically to simulate the pro- 
gress curve [P] -- F(t) [16]. The latter was compared with the collected 
experimental data and unknown parameters were determined by non- 
linear egression analysis. Kia and K~b were obtained from the v~a/v0 and 
Vib/vo ratios (see Fig. 1) as described [4]. If korr was known (see section 
3.2), kon was calculated as kon = korr/Ki, else the value of ko. for rCC 
(1.3xl07M-~.s -1) was substituted and kor f was calculated as 
ko~f = ko,K ~. 
3. Results and discussion 
3.1. Repurification of  papain 
Papain (Sigma or Boehringer) repurified by ion-exchange 
chromatography yielded a homogeneous N-terminal sequence 
and contained virtually no cystatin-resistant activity due to 
PPIV as assayed with the substrate Boc-Ala-Ala-GIy- 
NHPhNO> PPIV activity (not inhibited by chicken cystatin) 
was found in a well separated peak and was isolated for use in 
control experiments (data not shown). 
3.2. Kinetic model of  temporary inhibition 
The preparation and characterization f hairpin loop vari- 
ants of recombinant chicken cystatin is described elsewhere [4]. 
The temporary nature of papain inhibition by these variants 
(Table 1) was discovered in experiments with enzyme concen- 
trations above 0.5 nM. Inhibition experiments with lower en- 
zyme concentrations for determination f K~ and rate constants 
did not reveal any reappearance of enzymatic activity even 
when observed over several hours. No temporary inhibition 
was seen with wild type-like recombinant chicken cystatin 
(rCC), the parent molecule of the variants [7]. 
A typical experiment showing temporary inhibition of pa- 
pain by the AV55-$56 (first hairpin loop) deletion variant of 
chicken cystatin is presented in Fig. 1. After rapid initial inhibi- 
tion, papain activity reappears and raises slowly until a second, 
stable equilibrium is reached. Using a simulation program (see 
section 2.6), several kinetic mechanisms have been tested for 
their consistence with the experimental data. One mechanism 
that was able to describe all experimental data properly is the 
rapid formation of an initial enzyme-inhibitor complex, EIa, 
(equilibrium dissociation constant Kia) followed by its slow (i.e. 
rate limiting) conversion into a less stable complex, EIb, which 
dissociates rapidly towards a new equilibrium (Kib). The first 
order rate constant of the conversion, ktemp , was determined by 
nonlinear egression analysis on the basis of the postulated 
mechanism. Table 1 summarizes the results for variants that 
have been found to be temporary inhibitors of papain. With 
three of the variants, V55D, AP103-L105 and AI102-Q107, sig- 
nificant inhibition by the converted complex (EIb, /fib) was not 
detected at the applied inhibitor concentrations; in these cases 
restoration of full initial reaction rate was observed. 
The proposed kinetic mechanism (Fig. 1) is consistent with 
the observed ependance of inhibition on enzyme concentra- 
tion [4] and on inhibitor concentration (Fig. 2). Reappearence 
of enzyme activity showed a characteristic sigrnoidal course as 
it has been observed earlier with temporary synthetic inhibitors 
of trypsin [17]. The initial 'lag' phase is explained by the saturat- 
ing effect of inhibitor concentrations much higher than K~a; its 
duration increased with inhibitor concentration as expected 
Table 1 
Temporary inhibition of papain by hairpin loop variants of chicken cystatin 
Inhibitor variant gia korf~ ktemp Klb ktemr,/gia 
(nM) (s -l) (s -l) (nM) (s -1. M -l) 
V55D 0.92 1.2 x 10 -2 1.96 × 10 -3 n.d. 2.13 × 10 6 
AV55 361 n.d. 4.80 × 10 -1 3012 1.33 × 10 6 
AV55-$56 741 n.d. 4.90 × 10 -r 10,020 0.66 × 10 6 
AP103-L105 2.15 1.1 × 10 -2 1.78 × 10 -3 n.d. 0.83 × 10 6 
AI102-QI07 2.00 n.d. 2.28 x 10 -3 n.d. 1.14 × 106 
Substrate K,, kco, kcat] gm 
~M) (s-') (s-'. M -m) 
Z-Phe-Arg-NHMec 52.4 9.16 × 10 ~ 1.75 × 10 -6 
Data of the fluorogenic peptide substrate Z-Phe-Arg-NHMec determined in our laboratory were included for comparison (lower part of the table). 
See main text and Fig. 1 for definition of constants, n.d., not determined (see text for explanation). 
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! ig. 1. Temporary inhibition of papain by the AV55-$56 deletion vari- 
~nt of recombinant chicken cystatin: Proposed kinetic mechanism and 
li t of simulated progress curve to experimental data. Continuous assay 
~,f papain activity with the substrate Bz-Arg-NHMec (10 #M). After 
t~fiol activation of papain (2.4 nM), the AV55-$56 variant (2.6 #M) was 
added (arrow). [P], concentration f the fluorescent reaction product 
~minomethyl coumarin; v, reaction rate; Vo, initial reaction rate before 
~ddition of the inhibitor; v~, reaction rate after formation of the initial 
enzyme-inhibitor complex; v~b, reaction rate at the end of the conver- 
~-ton. On the basis of the proposed mechanism (upper part of the panel), 
-imulated progress curves for [P] and v (solid lines) were fitted to the 
, xperimental data (represented bydots, 2 samples/rain). 
~rom the simulations. Very similar values of ktemp were obtained 
~rom experiments with varying enzyme and inhibitor concen- 
trations (see Fig. 2). With two of the variants, the dissociation 
ate constants of the initial complex, kon'a, could be determined 
ruder conditions of low enzyme concentration when temporary 
inhibition is not significant (see Table 1). kon'a was found to be 
iligher than the corresponding ktemp , indicating that the conver- 
don step is rate-limiting rather than dissociation of the initial 
mzyme-inhibitor complex. 
~.3. Cleavage of the inhibitor variants 
The predicted conversion of the inhibitor into a 'modified' 
form with changed structure was confirmed by SDS-PAGE of 
mixtures of papain with the inhibitor variants, as shown for the 
V55D (first hairpin loop) variant in Fig. 3A. The time course 
of disappearance of the unmodified inhibitor determined by 
densitometry of the SDS gel correlated well with that predicted 
on the basis of inhibition kinetics (Fig. 3B). The initial rate of 
disappearance of EIa, i.e. the slope of the straight line in Fig. 
3B, is expected to be first order with respect o the concentra- 
tion of unmodified complex, v = ktemp[EIa]. As the experiment 
was performed under titration conditions ([Et]/Ki, = 400), the 
enzyme binds stoichiometrically and, as long as [I~] > [Et], then 
[EIJ = [E,]. The value of ktemp calculated from this approach to 
1.94 × 10 -3 s -t was in agreement with the value of 1.96 × 10 -3 
s -~ calculated from inhibition experiments ( ee Table 1). 
N-terminal sequencing of incubated mixtures of papain with 
the inhibitor variants revealed that the conversion was always 
due to the cleavage of a single peptide bond, Glyg-Ala ~°, giving 
rise to a truncated form of the cystatin variant beginning with 
Ala r°, which is expected to be a weaker inhibitor than the 
full-length form of the inhibitor variant [18,19]. Cleavage goes 
to completion; after long incubation times, however, additional 
minor cleavages were observed at various exposed sites of the 
inhibitor molecule (data not shown). Cleavage of the Gly9-Ala 1° 
bond by contaminating papaya proteinase IV (PPIV), which is 
not inhibited by cystatins [6], can be excluded after careful 
purification of papain by ion exchange chromatography fol- 
lowed by negative assay of PPIV activity (see section 3.1). 
Addition of purified PPIV to the inhibition assays did not 
change the progress curves up to 15% PPIV (molar ratio). 
Further increase of the PPIV/papain ratio shifted the progress 
curves gradually towards a pattern predicted for a mechanism 
where the free inhibitor is cleaved by a second, non-inhibited 
enzyme (data not shown). 
Inhibition of human cathepsin L by several hairpin loop 
mutants was also found to be temporary, suggesting that tem- 
porary inhibition by certain cystatin variants is a general prop- 
erty of cysteine proteinases rather than being restricted to pa- 
pain. However, both gia and ktemp were 1-2 orders of magnitude 
lower than with papain (e.g. 0.046 nM and 1.1 x 10 -4 s -~ for the 
AV55-$56 variant or 0.0029 nM and 2.8 x 10 -5 s -~ for the 
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Fig. 2. Temporary inhibition of papain by the API03-L105 deletion 
variant of recombinant chicken cystatin: Effect of inhibitor concentra- 
tion. Continuous assays of papain (4.4 nM) with increasing concentra- 
tions of the/IP103-L105 variant: 7.3 nM (1), 14.6 nM (2), 29.1 nM (3). 
(A) concentrations of the fluorescent reaction product aminomethyl 
coumarin; (B) reaction rates. Simulated progress curves (solid lines) 
were fitted to the experimental data (dots) on the basis of the proposed 
mechanism (see Fig. 1). kte,, p estimated from these fits were 
1.77 × 10 -3 s -1 (1), 1.80 × 10 -3 s -1 (2), and 1.74 × 10 -3 s -[ (3), 
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Fig. 3. Cleavage of the V55D substitution variant by papain. Papain (0.4/aM) was incubated with the V55D variant (4/aM) in 0.3 M sodium acetate, 
2 mM EDTA, 0.05% Brij 35, 1 mM dithiothreitol, pH 5.5 at 30°C. The reaction was stopped after the indicated times by addition of 0.025 M sodium 
monochloroacetate. (A) SDS-PAGE of incubation mixtures. (B) Time-dependent disappearance of the unmodified inhibitor (upper band) as 
determined by densitometry of the SDS gel. The dotted line was obtained by linear egression analysis of the first six data points. 
AP103-I105 variant), necessitating experiments with high con- 
centrations of cathepsin L and recombinant chicken cystatin 
variants. For these reasons the peptide bond cleaved by cathep- 
sin L has not yet been identified by sequence analysis. Interest- 
ingly, we have not been able to detect emporary inhibition of 
cathepsin B in preliminary experiments performed with high 
enzyme concentrations (70 nM) and long incubation times. 
The Ala-form of natural chicken cystatin, as it would result 
from cleavage of the Glyg-Ala 1° bond, has a 20,000-fold higher 
K~ value with papain than the intact inhibitor [18,19]. The same 
type of N-terminal truncation raised the Ki of the AV55 and 
AV55-$56 variants by only a factor of 8.3 and 13.5, respectively 
(calculated as gib]Kia from the data in Table 1). This marked 
discrepancy suggests that the binding mode of the variants 
containing distorted hairpin loop sequences i different from 
that of the wild type. The contribution of the N-terminal con- 
tact area to complex formation (before cleavage of the Gly 9- 
Ala 1° bond) seems to be much less important in the mutants 
than in the wild type with intact loops. Recently Hall et al. 
reported a similar low effect on affinity on truncation of vari- 
ants of cystatin C in which Gly 11 (corresponding to Gly 9 of 
chicken cystatin) was replaced by bulky residues, disturbing the 
conformation of the N-terminal contact area [20]. 
3.4. Inhibitor variants as substrates 
Combining evidence from inhibition kinetics and amino acid 
sequencing, the observed temporary inhibition of papain by 
hairpin loop mutants is explained by cleavage of the Glyg-Ala ]° 
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papain + cystatin mutant 
"inhihitor-like" binding 
cystatin mutant 
 J.gU ~ ~ ~. - -~ 
Q 
11 
L 
"substrate-like" binding 
1 cys-..t 1 
papain 
trunk cleavage 
I ig. 4. Temporary inhibition of papain by cystatin mutants in the 'elephant-trunk model' [18,27]. The mutant can adopt 'inhibitor-like' or 
',ubstrate-like' binding modes; the latter brings the Glyg-Ala ~° bond within the N-terminal 'trunk' in the vicinity of the active site Cys zS, resulting 
i i  its cleavage. Two possible mechanisms can be proposed: (1) competition of inhibitor-like and substrate-like complexes for free papain; or 
I ~) rearrangement of he inhibitor-like conformation by 'slippage' in the hydrophobic environment. 
t,ond of the inhibitors. Due to the proposed kinetic model, we 
~, aggest hat this cleavage occurs within the initial complex of 
l he enzyme with the non-modified inhibitor variant and is fol- 
1,~wed, epending on K~b, by at least partial dissociation of the 
~aodified inhibitor variant from the enzyme. 
Gly 9 is strictly conserved within the superfamily of cystatins 
[21]. Various structural and functional evidence has been pre- 
~ented that the residues preceding Gly 9 of chicken cystatin or 
~he homologous Gly ~ in cystatin C bind in the putative $2 and 
~';3 subsites of papain and are essential for effective inhibition 
I 18-20,22]. These findings uggest a formal analogy of the Gly 9- 
\ la 1° bond of chicken cystatin with the 'scissile bond' in the 
eactive site of small serine proteinase inhibitors, which is fre- 
, luently cleaved in the enzyme-inhibitor complex according to 
he so called 'standard mechanism' [5,23,24]. Structural data do 
lot support his analogy, however: in the docking model of the 
)apain-chicken cystatin complex and in the experimental struc- 
ure of the stefin B-papain complex, the Gly9-Ala ~° bond is 
,patially removed from the catalytic Cys 25 residue of papain 
md thus seems to be not cleavable [25-27]. Indeed, no experi- 
nental evidence has been reported until now for a cleavage of 
he Gly9-Ala ~° or corresponding peptide bond within the com- 
plexes of wild type cystatins or stefins or recombinant mutants 
) f  these inhibitors. Cleavage of excess chicken cystatin or cys- 
atin C at the Gly9-Ala t° or Gly ~l-Gly~2 bond by non-repurified 
-ommercial papain [5] has been explained retrospectively b  
PPIV contamination of the papain used in these experiments 
16]. Cleavages due to the attack of excess papain on the complex 
~aave been observed recently with cystatin C in exposed regions 
such as the Gly4-Lys 5and the HisS6-Asp 87 bond [28]. This type 
of mechanism, whereby a second free papain molecule acts on 
the papain-inhibitor complex, can be excluded in our work as 
cleavage was observed even with a ten-fold molar excess of 
inhibitor over papain under titration conditions, when virtually 
no free enzyme is expected (see Fig. 3B). 
We hypothesize that severe distortion of binding in one of 
the two hairpin loop regions can change the overall binding 
mode of the inhibitor in a way that the Glyg-Ala t° bond moves 
closer to the active-site Cys z5 of papain and becomes cleavable 
in a substrate-like manner. Hydrophobic contacts dominate the 
papain-cystatin interaction [25,26]; these relatively non-specific 
contacts are supplemented bya small number of polar contacts 
that anchor the two components. That certain mutations lead 
to cleavage of the molecule suggest hat these interactions are 
finely balanced. Temporary inhibition arises as a result of two 
modes of enzyme-inhibitor binding; one 'inhibitor-like' and 
one 'substrate-like' (Fig. 4). These modes presumably share 
comparable interactions at the $2 and $3 subsites, fixing the 
amino terminus. In the case of'inhibitor-like' binding, the Gly 9- 
Ala 1° bond is removed from the active site [25,26]. Upon 'sub- 
strate-like' binding, however, this bond approaches Cys 25 re- 
sulting in its cleavage. Unlike the 'canonical inhibitors' of serine 
proteinases [23,24,27], the cleavage products are free to diffuse 
away from one another, leading irreversibly to the truncated 
form. If the two hairpin loops of the truncated mutant are able 
to make sufficient favorable contacts, then a second inhibition 
constant will be seen. Attainment of the 'substrate-like' state 
can occur via two pathways (Fig. 4): (i) inhibitor-like and sub- 
strate-like conformations compete for free papain; irreversible 
cleavage of the substrate form shifts the equilibrium to the 
truncated form; (ii) after binding in an inhibitor-like fashion, 
the cystatin mutant 'slips' through the active site cleft, adopts 
the substrate-like binding mode, and becomes cleaved. 
Both pathways eem compatible with the kinetic data of 
Table 1. In a rough approximation, cleavage of the inhibitor 
can be described by a Michaelis-Menten mechanism where K~a 
190 W. Machleidt et al./FEBS Letters 361 (1995) 185 190 
is equivalent o Km and ktemp to kca t. Formally the inhibitor 
variants may be considered as 'substrates' with low K~ and low 
k~at; therefore inhibition dominates and the cleavage reaction 
is very slow at low enzyme concentrations. With increasing K~,, 
i.e. decreasing stability of the initial complex, ktemp also in- 
creases, suggesting that the putative transition state(s) leading 
to the cleavage reaction is (are) energetically favored relative 
to the inhibitor-like state [29]. This is consistent with the obser- 
vation that for the interaction of cathepsin L with the AP103- 
L105 variant both the Kia (0.0029 nM) and ktemp (2.8 × 10 -5 s -l) 
were markedly lower than for the interaction of papain with the 
same mutant (see Table 1), reflecting the greater 'insensitivity' 
of cathepsin L to inhibitor mutations [4]. The specificity con- 
stant, ktemp[gm, which is considered as a measure of the cata- 
lytic efficiency of an enzyme [24], was found to be very similar 
for temporary inhibition of papain by all inhibitor variants and 
is close to the value of kcat /g  m for Z-Phe-Arg-NHMec, a good 
peptide substrate of papain (see Table 1). Assuming a ktemp] gia 
value of 1 × 106 s -~M -1, the ktemp of papain and wild type 
chicken cystatin (K~ < 1 × 10 -12 M) can be extrapolated as <10 -6 
s -~, implying that cleavage of the Gly9-Ala ~° bond of the natural 
inhibitor, if there is any, is too slow to be readily detectable. 
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